Skip to content

Apremilast

Otezla (apremilast) is a small molecule pharmaceutical. Apremilast was first approved as Otezla on 2014-03-21. It is used to treat psoriatic arthritis in the USA. It has been approved in Europe to treat psoriasis and psoriatic arthritis. The pharmaceutical is active against cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4D, cAMP-specific 3',5'-cyclic phosphodiesterase 4C, and cAMP-specific 3',5'-cyclic phosphodiesterase 4A. Otezla's patents are valid until 2034-05-29 (FDA).
Trade Name Otezla
Common Name Apremilast
Indication psoriasis, psoriatic arthritis
Drug Class Antiasthmatics/antiallergics: type IV phosphodiesterase inhibitors
Apremilast
Get full access now